Tomohiro Terada, Ph.D. Professor
The aim of our laboratory is to contribute to the provision of pharmaceutical care with safety and high quality by 1) promoting individualization and optimization of drug therapy (Drug Fostering and Evolution), 2) to identify the mechanisms and molecules involved in the development of diseases and adverse drug reaction, and to propose new therapeutic and preventive drugs (Drug development), and 3) disseminating new evidence on pharmacist services. To this end, we are promoting so-called “Reverse Translational Research” (Fig. 1). We are convinced that the logical thinking and sense acquired through research will enable us to break new ground as clinical pharmacists.
Research and Education[Research] We are promoting the following clinical problem-solving research (Fig. 2).
1) Establishment of individualization of pharmacotherapy for immunosuppressive drugs and antibody drugs
2) Elucidation of the mechanisms of adverse drug reactions and development of novel strategy for management
3) Research on the optimal usage of pharmaceuticals and the establishment of novel pharmacist practices
We have identified a new mechanism of chemotherapy-induced peripheral neuropathy, and are trying to develop a causal therapy. In addition, we are conducting clinical research using medical information databases and devising patient-specific dosage design methods based on pharmacokinetic models.
[Education] The graduate students of the Graduate School of Medicine and Graduate School of Pharmaceutical Sciences are enrolled in our laboratory. They are working on the above issues in collaboration with the doctors and pharmacists. In addition, pharmacists who wish to solve clinical problems also conduct research under the guidance of faculty members.
We are looking forward to those who want to pursue the science of “Pharmacotherapy” and create new evidence for pharmacists’ work.
Figure 1. Flowchart of Reverse Translational Research Promotion
Figure 2. Themes and research goals pursued in our laboratory
- Itohara K, Yano I, Tsuzuki T, Uesugi M, Nakagawa S, Yonezawa A, Okajima H, Kaido T, Uemoto S, Matsubara K: A Minimal physiologically-based pharmacokinetic model for tacrolimus in living-donor liver transplantation: perspectives related to liver regeneration and the cytochrome P450 3A5 (CYP3A5) genotype. CPT Pharmacometrics Syst Pharmacol, 8: 587-595 (2019)
- Jin C, Yonezawa A, Yoshimatsu H, Imai S, Koyanagi M, Yamanishi K, Nakagawa S, Itohara K, Omura T, Nakagawa T, Nagai J, Matsubara K: Effect of riboflavin deficiency on development of the cerebral cortex in Slc52a3 knockout mice. Sci Rep, 10: 18443 (2020)
- Ikuta K, Nakagawa S, Momo K, Yonezawa A, Itohara K, Sato Y, Imai S, Nakagawa T, Matsubara K: Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study. BMJ Open, 11: e041543 (2021)
- Koyanagi M, Imai S, Matsumoto M, Iguma Y, Kawaguchi-Sakita N, Kotake T, Iwamitsu Y, Ntogwa M, Hiraiwa R, Nagayasu K, Saigo M, Ogihara T, Yonezawa A, Omura T, Nakagawa S, Nakagawa T, Matsubara K: Pro-nociceptive roles of Schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy. Cancer Res, doi: 10.1158/0008-5472.CAN-20-2799. Online ahead of print (2021)
- Koyanagi M, Imai S, Iwamitsu Y, Matsumoto M, Saigo M, Moriya A, Ogihara T, Nakazato Y, Yonezawa A, Nakagawa S, Nakagawa T, Matsubara K: Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation. Neuropharmacology, 188: 108514 (2021)
Clinical Pharmacology and TherapeuticsProfessor: Tomohiro Terada, Ph.D.
Associate Professor: Takayuki Nakagawa, Ph.D.
Senior Lecturer: Satoshi Imai, Ph.D.
Assistant Professor: Shunsaku Nakagawa, Ph.D., Kotaro Itohara